Zacks Investment Research lowered shares of Cascadian Therapeutics, Inc. (NASDAQ:CASC) from a buy rating to a hold rating in a report published on Tuesday morning.
According to Zacks, “Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company’s product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. “
Other equities analysts have also recently issued reports about the company. Barclays PLC began coverage on Cascadian Therapeutics in a research note on Wednesday, September 6th. They issued an underweight rating and a $4.00 price target on the stock. Cowen and Company reaffirmed a buy rating on shares of Cascadian Therapeutics in a research note on Wednesday, August 9th. Cantor Fitzgerald reaffirmed a hold rating and issued a $4.00 price target on shares of Cascadian Therapeutics in a research note on Thursday, August 31st. Finally, ValuEngine cut Cascadian Therapeutics from a sell rating to a strong sell rating in a research note on Friday, September 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $5.63.
Cascadian Therapeutics (NASDAQ:CASC) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.01. During the same period in the prior year, the company posted ($0.09) earnings per share. sell-side analysts forecast that Cascadian Therapeutics will post -1.27 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its stake in shares of Cascadian Therapeutics by 423.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 511,899 shares of the biopharmaceutical company’s stock valued at $2,094,000 after purchasing an additional 414,019 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Cascadian Therapeutics by 6,622.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 89,413 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 88,083 shares in the last quarter. P.A.W. Capital Corp acquired a new stake in shares of Cascadian Therapeutics in the 3rd quarter worth $982,000. California State Teachers Retirement System acquired a new stake in shares of Cascadian Therapeutics in the 2nd quarter worth $226,000. Finally, State Street Corp lifted its position in Cascadian Therapeutics by 1,113.7% during the 2nd quarter. State Street Corp now owns 411,299 shares of the biopharmaceutical company’s stock worth $1,527,000 after acquiring an additional 377,410 shares during the period. 83.03% of the stock is owned by institutional investors.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Cascadian Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cascadian Therapeutics Inc. and related companies.